{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:24:29Z","timestamp":1791321869937,"version":"4.3.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.clml.2011.03.003","type":"journal-article","created":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T14:10:12Z","timestamp":1302876612000},"page":"219-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Multicenter Photopheresis Intervention Trial in Early-Stage Mycosis Fungoides"],"prefix":"10.1016","volume":"11","author":[{"given":"Rakhshandra","family":"Talpur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Francis","family":"Demierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Geskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elma","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvina","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley","family":"Eubank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Zic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald R.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Bohjanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.03.003_bib1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.003_bib2","first-page":"561","article-title":"Proceeding of the Workshop on Cutaneous T-cell Lymphomas (mycosis fungoides and Sezary syndromes)","volume":"63","author":"Lamberg","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clml.2011.03.003_bib3","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI24826","article-title":"Immunopathogenesis and therapy of cutaneous T cell lymphoma","volume":"115","author":"Kim","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2011.03.003_bib4","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States 1973-2002","volume":"143","author":"Criscione","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2011.03.003_bib5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.7326\/0003-4819-100-2-187","article-title":"Clinical staging for cutaneous T-cell lymphoma","volume":"100","author":"Lamberg","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2011.03.003_bib6","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.003_bib7","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1080\/10428190600709655","article-title":"S\u00e9zary cell counts in erythrodermic cutaneous T-cell lymphoma: implications for prognosis and staging","volume":"47","author":"Vonderheid","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2011.03.003_bib8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/jid.1962.106","article-title":"The presently known distributions of furocoumarins (psoralens) in plants","volume":"39","author":"Pathak","year":"1962","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clml.2011.03.003_bib9","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jaad.2009.02.039","article-title":"Extracorporeal photopheresis: past, present, and future","volume":"61","author":"Knobler","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clml.2011.03.003_bib10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/sj.bmt.1700710","article-title":"Prevention and treatment of acute GVHD: the old and the new","volume":"19","author":"Lazarus","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2011.03.003_bib11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy","volume":"316","author":"Edelson","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.03.003_bib12","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0889-8588(18)30062-5","article-title":"Photopheresis for the treatment of cutaneous T-cell lymphoma","volume":"9","author":"Lim","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2011.03.003_bib13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2141.1999.01773.x","article-title":"ECP induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and GVHD patients","volume":"107","author":"Bladon","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.03.003_bib14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/292060a0","article-title":"Vaccination against autoimmune encephalomyelitis with T lymphocyte line cells reactive against myelin basic protein","volume":"292","author":"Ben-Nun","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.clml.2011.03.003_bib15","doi-asserted-by":"crossref","first-page":"5968","DOI":"10.4049\/jimmunol.174.10.5968","article-title":"Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells","volume":"174","author":"Maeda","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.clml.2011.03.003_bib16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/TP.0b013e3181aed927","article-title":"Extracorporeal photophoresis augments function of CD4+CD25+FoxP3+ regulatory T cells by triggering adenosine production","volume":"88","author":"Schmitt","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.clml.2011.03.003_bib17","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1097\/TP.0b013e3181a27a5d","article-title":"Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells","volume":"87","author":"Di Biaso","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.clml.2011.03.003_bib18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clim.2009.08.016","article-title":"Cutaneous T cell lymphoma and graft-versus-host disease: a comparison of in vivo effects of extracorporeal photochemotherapy on Foxp3+ regulatory T cells","volume":"133","author":"Rao","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clml.2011.03.003_bib19","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1182\/blood-2004-06-2181","article-title":"Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells","volume":"105","author":"Berger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.003_bib20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3816\/CLM.2006.n.063","article-title":"High clinical response rate with multimodality immunomodulatory therapy for Sezary syndrome","volume":"7","author":"Richardson","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2011.03.003_bib21","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for the treatment of refractory advanced stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.003_bib22","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2011.03.003_bib23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1396-0296.2003.01643.x","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"16","author":"Olsen","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clml.2011.03.003_bib24","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/cncr.22596","article-title":"Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma","volume":"109","author":"Straus","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.03.003_bib25","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/archderm.138.8.1054","article-title":"Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution","volume":"138","author":"Suchin","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2011.03.003_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/12034754030070S402","article-title":"Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2003","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.clml.2011.03.003_bib27","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0889-8588(18)30060-1","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"9","author":"Olsen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2011.03.003_bib28","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"A Phase IIb Multicenter Trial of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with persistent, progressive, or treatment refractory mycosis fungoides or Sezary syndrome subtypes of cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.003_bib29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2002.118538","article-title":"Update on erythrodermic cutaneous T-cell lymphoma: Report on the International Society for Cutaneous Lymphomas","volume":"46","author":"Vonderheid","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clml.2011.03.003_bib30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/1523-1747.ep12285650","article-title":"Convergen and discriminant validity of a geneeric and disease-specific instrument to measure quality of life in patients with skin disease","volume":"108","author":"Chren","year":"1997","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clml.2011.03.003_bib31","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","article-title":"SF-36 health survey update","volume":"25","author":"Ware","year":"2000","journal-title":"Spine (Phila Pa 1976)"},{"key":"10.1016\/j.clml.2011.03.003_bib32","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.003_bib33","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1158\/1078-0432.CCR-0721-03","article-title":"CD25 expression in cutaneous T-cell lymphoma is dependent on tissue microenvironment: implications for targeted therapy","volume":"10","author":"Jones","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.03.003_bib34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6890-2-5","article-title":"A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy","volume":"2","author":"Washington","year":"2002","journal-title":"BMC Clin Pathol"},{"key":"10.1016\/j.clml.2011.03.003_bib35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.clml.2011.03.003_bib36","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the Revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer Staging Proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.003_bib37","unstructured":"Perrin B, Morrissey K, Vittorio CC, et al. Predictors of blood involvement in stage IA Mycosis Fungoides Patients. Abstract 33, World Congress of Cutaneous Lymphoma, Northwestern, Chicago, Illinois, September 23, 2010."},{"key":"10.1016\/j.clml.2011.03.003_bib38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2133.2005.06857.x","article-title":"Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group","volume":"154","author":"McKenna","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clml.2011.03.003_bib39","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2133.2007.08415.x","article-title":"Consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease","volume":"158","author":"Scarisbrick","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clml.2011.03.003_bib40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1067\/mjd.2000.104852","article-title":"Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution","volume":"43","author":"Bisaccia","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clml.2011.03.003_bib41","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-4362.1991.tb04795.x","article-title":"Extracorporeal photochemotherapy in the treatment of cutaneous T-cell lymphoma","volume":"30","author":"Oziemski","year":"1991","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clml.2011.03.003_bib42","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0190-9622(96)90683-0","article-title":"Photopheresis therapy for cutaneous T-cell lymphoma","volume":"35","author":"Duvic","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clml.2011.03.003_bib43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1396-0296.2003.01646.x","article-title":"The treatment of cutaneous T-cell lymphoma with photopheresis","volume":"16","author":"Zic","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clml.2011.03.003_bib44","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1473-0502(02)00103-9","article-title":"Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma","volume":"28","author":"Knobler","year":"2003","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.clml.2011.03.003_bib45","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.2741\/3566","article-title":"Extracorporeal photoimmunotherapy-photopheresis","volume":"14","author":"Dani","year":"2009","journal-title":"Front Biosci"},{"key":"10.1016\/j.clml.2011.03.003_bib46","first-page":"85","article-title":"Photopheresis: clinical application and mechanism of action","volume":"4","author":"Rook","year":"1999","journal-title":"JID Symp Proc"},{"key":"10.1016\/j.clml.2011.03.003_bib47","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0190-9622(96)90119-X","article-title":"Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution","volume":"35","author":"Gottlieb","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clml.2011.03.003_bib48","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1067\/mjd.2002.124607","article-title":"Optimizing bexarotene therapy for cutaneous T-cell lymphoma","volume":"47","author":"Talpur","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clml.2011.03.003_bib49","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2009.09037.x","article-title":"Bexarotene therapy for mycosis fungoides and S\u00e9zary syndrome","volume":"160","author":"Abbott","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clml.2011.03.003_bib50","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(89)70049-9","article-title":"Interferon alfa-2a in the treatment of cutaneous T-cell lymphoma","volume":"20","author":"Olsen","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clml.2011.03.003_bib51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1600-0781.2007.00300.x","article-title":"Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma","volume":"23","author":"Miller","year":"2007","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.clml.2011.03.003_bib52","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-4632.2009.03771.x","article-title":"Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma","volume":"48","author":"Vidulich","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clml.2011.03.003_bib53","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0190-9622(97)80226-5","volume":"36","author":"Demierre","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clml.2011.03.003_bib54","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0889-8588(03)00106-0","article-title":"Selective immunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow","volume":"17","author":"Girardi","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2011.03.003_bib55","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/archderm.135.5.600","article-title":"S\u00e9zary syndrome, cutaneous T-cell lymphoma, and extracorporeal photopheresis","volume":"135","author":"Edelson","year":"1999","journal-title":"Arch Dermatol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:21:45Z","timestamp":1761870105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S2152265011000048"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.03.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicenter Photopheresis Intervention Trial in Early-Stage Mycosis Fungoides","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}